34,912 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by JPL Wealth Management LLC

JPL Wealth Management LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 34,912 shares of the biopharmaceutical company's stock, valued at approximately $3,225,000.

Other institutional investors have also recently made changes to their positions in the company. HHM Wealth Advisors LLC grew its position in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 154 shares during the period. YANKCOM Partnership acquired a new stake in Gilead Sciences during the fourth quarter valued at $28,000. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $29,000. Crews Bank & Trust acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $31,000. Finally, Stephens Consulting LLC grew its position in shares of Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 260 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Bank of America lifted their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Wolfe Research started coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They set an "outperform" rating and a $110.00 price target on the stock. Oppenheimer boosted their price target on shares of Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 4th. Citigroup started coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They set a "buy" rating and a $125.00 price target on the stock. Finally, Piper Sandler boosted their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average target price of $104.52.

Remove Ads

Gilead Sciences Price Performance

Shares of GILD stock opened at $113.99 on Thursday. The firm has a market cap of $141.96 billion, a price-to-earnings ratio of 308.08, a PEG ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The stock has a 50-day moving average price of $100.99 and a 200 day moving average price of $92.33. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.77%. Gilead Sciences's dividend payout ratio (DPR) is currently 854.05%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction on Monday, March 10th. The stock was sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the sale, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $19,977,938.37. This trade represents a 9.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 311,285 shares of company stock valued at $31,284,910 over the last 90 days. Company insiders own 0.16% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.